Which vaccine schedule works best? new study aims to protect babies from pneumococcal disease
NCT ID NCT07591181
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two schedules (2+1 vs 3+1 doses) of a 13-valent pneumococcal vaccine in 210 healthy infants starting at 2 months old. Researchers will measure antibody levels and track side effects to find the best way to prevent pneumococcal infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13)
- What this could lead to
- If successful, this could help determine the most effective and safe vaccination schedule to protect infants from pneumococcal disease.
- What could go wrong
- This is an early-stage study with only 210 participants, so results may not apply broadly. The vaccine may not show clear differences between schedules.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.